Clin Nucl Med. 2018 Jun;43(6):e184-e185. doi: 10.1097/RLU.0000000000002077.
Meningiomas are typically benign solitary intracranial tumors. Atypical (World Health Organization [WHO] grade II) or malignant/anaplastic (WHO grade III) meningiomas are seldom, and distant metastases occur only in rare exceptions. We present a case of a 54-year-old male patient with atypical (WHO grade II) meningioma who underwent 1 cycle of peptide receptor radionuclide therapy. Previous imaging studies were confined to the head, but posttherapeutic whole-body Lu-DOTATATE scintigraphy revealed thoracic uptake arising from previously undetected pulmonic meningioma metastases. The case highlights the importance of consideration of rare/untypical metastatic sides and the value of radiotracer whole-body imaging in identifying these.
脑膜瘤通常为良性单发颅内肿瘤。非典型(世界卫生组织[WHO] 分级 II)或恶性/间变(WHO 分级 III)脑膜瘤较为少见,远处转移仅罕见情况下发生。我们报告了 1 例 54 岁男性患者,患有非典型(WHO 分级 II)脑膜瘤,接受了 1 个周期的肽受体放射性核素治疗。之前的影像学研究仅限于头部,但治疗后全身 Lu-DOTATATE 闪烁显像显示,来自先前未检测到的肺脑膜瘤转移的胸部摄取。该病例强调了考虑罕见/非典型转移部位的重要性,以及放射性示踪剂全身成像在识别这些部位方面的价值。